105 related articles for article (PubMed ID: 29388070)
1. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response.
Behzad MM; Shahrabi S; Jaseb K; Bertacchini J; Ketabchi N; Saki N
Biochem Genet; 2018 Jun; 56(3):149-175. PubMed ID: 29388070
[TBL] [Abstract][Full Text] [Related]
2. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
3. Methylation status of RASSF1A in patients with chronic myeloid leukemia.
Avramouli A; Tsochas S; Mandala E; Katodritou E; Ioannou M; Ritis K; Speletas M
Leuk Res; 2009 Aug; 33(8):1130-2. PubMed ID: 19193434
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
5. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
Koschmieder S; Vetrie D
Semin Cancer Biol; 2018 Aug; 51():180-197. PubMed ID: 28778403
[TBL] [Abstract][Full Text] [Related]
8. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S
Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880
[TBL] [Abstract][Full Text] [Related]
9. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia.
Guinn BA; Mills KI
Leuk Lymphoma; 1997 Jul; 26(3-4):211-26. PubMed ID: 9322884
[TBL] [Abstract][Full Text] [Related]
11. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
[TBL] [Abstract][Full Text] [Related]
13. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T
Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
16. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Issa JP; Kantarjian H; Mohan A; O'Brien S; Cortes J; Pierce S; Talpaz M
Blood; 1999 Mar; 93(6):2075-80. PubMed ID: 10068681
[TBL] [Abstract][Full Text] [Related]
18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
19. Natural course and biology of CML.
Chereda B; Melo JV
Ann Hematol; 2015 Apr; 94 Suppl 2():S107-21. PubMed ID: 25814077
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]